StemCell Therapy

In the commercial fleet world, driver safety is above all, and it becomes even more crucial when a semi-trailer is hauling a couple of tons of dangerous or hazardous materials cross country. As weve witnessed in the past, the potential spills caused by the Oil & Gas industry fleets can cause immense environmental damage, if or when a mistake is made. Just the threat of a catastrophic oil spill hitting the news is poised to doom public opinion against the trucking company and supplier. Further highlighting the necessity for hazardous material drivers to stay alert and safe on the road, creating a potential problem that demands an innovative solution.

Israeli company Eyesight Technologies, which leverages AI and computer-vision technologies for a safe driving experience, announced that its partnering with French fleet management conglomerate GloboConnect, a leading provider of telematics systems for fleets.

"The partnership is a major part of our effort and investment to improve road safety," said Yannick GUIDEZ CEO of GloboConnect. "The addition of Eyesight Technologies' driver monitoring solution to our telematics capabilities enables us to extend our driver safety solutions to include monitoring inside the cabin, allowing our customers to ensure better driving practices and the safer transport of dangerous goods in the oil and gas trucking industry."

The joint venture will focus efforts towards developing a driver monitoring telematics device, tailored for the Oil & Gas industrys fleets. The device will combine Eyesight Technologies' computer vision and AI-based driver monitoring system (DMS) along with Globo's telematics infrastructure and hardware to improve road safety for an estimated 50,000 vehicles in oil & gas fleets.

"This partnership is another meaningful step towards creating safer driving environments in the fleet industry," said David Tolub, CEO of Eyesight Technologies. "An aftermarket DMS solution is a valuable addition to existing telematics offerings, increasing the safety and efficiency of fleets."

Read the original here:
Eyesight Technologies partners with GloboConnect to bring AI-driven safety to Oil & Gas Fleets - Geektime

Many of the animals, birds, and insects that are part of the Natural World have unique and useful uses and features related to their heads. This article covers a few of these which might explain such things as why a Dog tilt their heads when they hear a sound, and the Owl and the Praying Mantis are the only predators that have a special bone structure that is quite useful for them.

Now that I have covered Tails in article #1 let's move to the other half of our discussion on some of the unique features found in animals, birds, and insects in the natural world.

Just seeing a Dragonfly must be terrifying if you are a gnat, mosquito, or other small bugs. To us, humans, they are unique insects that are mostly quite nice to see. The eyes of a dragonfly take up 90% of its head. Their eyesight is the key to its hunting, and flying skills allow them to have a 95% success rate when hunting. They use this sight to judge the speed and trajectory of the target prey and adjust their flight to intercept the prey and snag it from the air.

The Common Mole's nose, found at the pointed end of its head, is the only part of its body it is not uncomfortable with. Despite devastating blindness and inadequate tactile sensitivity, the moles excel at finding food sources. Scientists have found that except for a few species of dogs such as the Bloodhound, which can tell the direction a smell comes from and follow it, the common mole may be the only animal with what is known as natural stereo smelling ability.

Look around, and maybe you can turn your head to the left or right and move it up and down with ease. You can also move your eyes around in many different directions, and a few of us can even cross our eyes. In the animal world, there are loads of various kinds of eyes that see the world in distinctive ways. Owls cannot move their eyeballs around in their sockets very well. Yet they do have particularly good night vision. Their eyes are positioned on the front of their heads like many of their fellow predators. They have what is thought of as binocular vision.

While Owls might not be able to move their eyeballs, they more this makeup for this by turning their heads up to 270 degrees to the right or left. That is more than twice what we humans can do. The owls have what is called a pivot joint in their bone structure that allows this broad range of movement. There is only one other predator that can do this. It is the Praying Mantis.

What is magnetite? It is a naturally occurring mineral that reacts to magnetic fields. Scientists believe that many animals may have small amounts of it in their brains, allowing them to sense the magnetic fields produced by the earth. However, Dolphins and some whales have magnetic rocks in their heads. Bats and birds (especially pigeons) can navigate vast distances without any clues as to where they are other than the presence and shape of the magnetic fields, which they sense using the magnetite in their brains. Dolphins and many species of whalecan navigate enormous miles of open ocean by using these same, but larger, rocks of this substance within their brains. They are navigating by the magnetic fields they have used during their entire life. They may even think they are in the open and deep waters but can be dangerously close to the shore.

Have you ever noticed that many species of Birds head-bob when they are walking? The term head-bobbing is used for the apparent back and forth movement of their head as they walk and is a bit of a misnomer. The birds do not bob their heads, ---instead, they move their body forward and leave their head behind. They then thrust their head forward past their body. This crazy behavior is thought to help critical aspects of their vision during their forward movement.

If you happen to see a deer bobbing its head, it is not like a bird. A deer's pupils are not like humans; instead, they are more oval and oriented horizontally to give them a wider field of view. We humans can see about a 120-degree range of vision. Having their eyes on the side of their head plus having the oblong pupils, a deer has close to a 300 degrees range. While this gives them a wider angle of vision, it does impact their vertical sight. That is one reason hunters sometimes use a tree stand. Because of this vertical limit, they bob their head to improve their vertical vision.

When you are out on Presque Isle, I am willing to bet that many of my readers think they see an eagle flying overhead. Well, most times, you have spotted a turkey vulture and not an eagle. While looking somewhat like an eagle, they have a genuine bald head while the eagle has white feathers. At close range, they resemble the wild turkey, hence their name. They are the only scavenger bird that cannot kill their prey. This is because their feet are like chickens and not an eagle's or a hawk's. Instead, they have a powerful beak that can tear through even the most robust cowhide. They also have an extraordinary sense of smell that allows them to locate a dead animal from over a mile away.

Monkeys use faces like name tags. They all boast the most colorful faces in the mammal kingdom, and they are not just for show. Like humans, they distinguish friend or foe by facial features, which have evolved to be uniquely distinctive in their close-knit communities.

Why do dogs tilt their heads when they hear sounds. The human ear is engineered to pick up a sound so efficiently that you do not need to turn toward the sound to capture it. That is not so with a dog. Dogs have flaps that partially or entirely cover the ear canal and serve as a barrier to sound. Luckily, the canine ear flap is moveable so the dog can easily make the necessary adjustment and tilt its head toward the sound.

Rabbit ears have a unique shape. Yes, they are long. However, they also have a curve that turns them into satellite dishes place upon a bunny's head. Their shape helps catch and amplify all sounds. Because rabbits are prey species, they must continuously monitor for small sounds that may show a predator is near. They also need to know where the sound is coming from. The length and their ability to move, turn and tilt their ears give rabbits a directional location of the sound. They also use their ears to signal other rabbits. People who have rabbits often tell that rabbits "waggle" their ears at their humans to get interaction from them.

In ending, I know there are many more different and interesting facts about animals, and I may in the future gather in some others and post here on Goerie.com.

See you on the park!!

Gene Ware is a published author of 9 books and is on the boards of the Presque Isle Light Station and was past Chairman of the Tom Ridge Center Foundation, and the Presque Isle Partnership. He is also a goerie.com contributing writer. Send questions and comments to ware906@gmail.com

Read more:
Heads or Tails - - The choice is up to you - - - Heads - Part #2 - GoErie.com

QUEENS A Bronx mother, who watched her only son rally from a gunshot wound to the head on July 4, 2019, mourned his loss outside the Queens rehab center where he spent the final months of his life.

He lived this for 13 months, Nicole Backmon said of her son Sammy, 21, outside the Park Terrace Care Center in Corona, Queens. He was a warrior.

Sammy Backmon was one face of gun violence in a city where most victims dont make headlines.

At age 20, he suffered a traumatic brain injury when he was hit by a bullet while coming home to the family apartment on Hull Avenue in the Bronx; he was celebrating the Fourth of July holiday.

He was walking home from the train and shots were fired, his uncle, Alex Rodriguez, said, and he got hit in the back of the head.

Sammy Backmon spent weeks in the intensive care unit at St. Barnabas Hospital, where he suffered brain damage that affected his speech, memory, mobility and eyesight.

The vision was really, really bad, Sammys uncle recalled. He couldnt see anything, except for a blurry silhouette.

But the family said Sammy Backmon improved remarkably after spending two months at Burke Rehab in White Plains. He was later transferred to the facility in Queens that accepted Medicaid payments.

His vision gradually got much better.

In February, wearing a helmet on his damaged skull, family cell phone videos showed physical therapists helping Sammy Backmon to start walking again.

He was almost walking independently, his mother said.

But the young man was having recurring issues with blood clots and circulation.

He made it through the height of the COVID-19 pandemic in new York without getting sick, but it did have an impact on his general health.

When COVID hit, PT really slowed down, Sammys uncle recalled. He started gaining weight, he wasnt moving, his circulation wasnt good.

Surgery to put a steel plate in Sammy Backmons head was repeatedly delayed.

On June 26, Sammy Backmon enjoyed a reunion with his extended family, dining outdoors in the Bronx after a visit to a medical clinic there.

His uncle took videos, joking it was Quarantine Friday, while one of Sammy Backmons little cousins ran around the table.

In late July, Sammy Backmon finally underwent the surgery to put the plate in his head where a piece of his skull used to be.

The family said it was a success.

But on August 10, Nicole Backmon got a call she wasnt prepared for.

Sammy Backmon, her only son, was dead at 21.

They think he had a seizure, Nicole Backmon said.

Sammy Backmons death certificate said he died of complications from a gunshot wound. His family wants an autopsy performed, and theyve started a GoFundMe page to defray funeral expenses.

His mother wants the public to know he endured a lot during the months he spent in a long-term care facility.

My son suffered in silence, Nicole Backmon said. He didnt tell me everything.

Read more from the original source:
Bronx son survived gunshot wound to head, but recovery took its toll, and his life - WPIX 11 New York

If you have problems with your eyesight and struggle to watch a lot of TV, Amazons latest update to its Fire TV platform could help resolve those issues.

Amazon has announced Text Banner for its Fire TV platform. Its an assistive technology designed for those with visual impairments and narrow field of vision, including conditions such as macular degeneration, glaucoma and retinitis pigmentosa.

Text Banner works by consolidating the onscreen text of a selected item/icon into a compact, rectangular banner that appears in a fixed location on the screen.

The entire Fire TV user interface, Prime Video and all apps on Fire TV work with Text Banner, which Amazon says makes it easier for these customers to enjoy movies, videos. Users can customise the feature by the changing colours as well as the size of the box and the text bu heading to Settings> Accessibility > Text Banner.

Marc Powell, Strategic Accessibility Lead at RNIB, said: The accessibility of tech is changing the lives of blind and partially sighted people giving a greater sense of freedom, increasing independence and breaking down barriers to create a more inclusive world.

Amazons move to begin making its Fire TV platform more accessible for people with vision impairment is another powerful message of inclusivity to the industry and we hope to continue seeing accessibility improve as a trend across the technology sector in the years ahead.

The Text Banner feature is available now. The cheapest available Fire TV Stick costs 44.99. Prime Video costs 7.99/month or you can get it as part of a Prime Membership, which costs 79/year.

TV & Audio Editor

Kob began his career at What Hi-Fi?, starting in the dusty stockroom before rising up the ranks to join the editorial and production team as the Buyers Guide editor. Experienced in both magazine and

Unlike other sites, we thoroughly review everything we recommend, using industry standard tests to evaluate products. Well always tell you what we find. We may get a commission if you buy via our price links.Tell us what you think email the Editor

Read the original:
Amazons latest Fire TV feature is designed to assist the visually impaired - TrustedReviews

The problem of mass death of birds from a wind turbine could be resolved through painting one blade black. That makes it easier for birds to avoid a deadly encounter, say the findings published in Ecology and Evolution.

The recent study found that painting one of the four white blades on a wind turbine black significantly decreases the number of dead birds by 72 per cent.

In fact, wind farms would kill twice as many bats as they do birds, the figures would be: 111 333 birds per turbine per year, and 222 666 bats per turbine/year, according to Mark Duchamp, head of Save the Eagles International.

According to the researchers from the Norwegian Institute for Nature Research conducted a trial on the remote island of Smola comparing how many birds were killed by four painted turbine compared to their untouched neighbours.

During seven and half years, the researchers regularly scoured the bottom of the turbines with specially trained sniffer dogs to identify any bird carcasses. The difference between periods when one of the four blades was painted black was impressive.

For the eight turbines included in the research four painted and four left bare a total of 1,275 searches were conducted between 2006 and 2016.

A total of 82 carcasses were found and statistical analysis revealed the birds which benefit the most from the pained blades are raptors and large soaring birds.

This includes eagles and vultures, who have been high-profile casualties of wind turbines. No white-tailed eagle carcasses were recorded after painting the blades.

The study also found that while the number of dead birds dropped at painted turbines, it did not trigger a spike in the number of casualties at neighbouring turbine zones. As the scientists suggest, the reason painting a single blade works is due to a phenomenon called motion smear.

This means that, although birds often have exceptional eyesight, the rotating blades appear invisible. Birds have extremely high-resolution eyesight in their peripheral field of vision, and the front-facing eyesight is not as good.

Thus, within assumed open airspace, birds may therefore not always perceive obstructions ahead thereby enhancing the risk of collision, the study says.

See original here:
Bird deaths from wind turbine's drop when one blade is painted black - PoliticalLore.com

Author and Motivational Speaker, Chad Foster

Chad Fosters life took a detour when he went blind in his late teens. Now hes an executive at Red Hat, the worlds largest open source software company, an author, and a motivational keynote speaker. His memoir, Blind Ambition (published by HarperCollins Leadership), will publish in early 2021.

I had the opportunity to interview Chad recently. Here are some of the highlights of that interview:

Jill Griffin: Take us back to when you lost your sight

Chad Foster: I was studying at the University of Tennessee when my eyesight really began fading. I was diagnosed at three-years-old with retinitis pigmentosa, a genetic eye condition, and doctors told my parents Id eventually go blind.

For me, it was really just an intellectual concept, because I played sports, drove a car, and other things people take for granted. I thought maybe Id be an outlier, but my eyesight started failing in college. Going blind changed the course of my life. It was a pretty dark time, but the fire inside of me didnt flame out.

Griffin: It must have been a challenging period. What was your response?

Foster: It was dreadful. Beyond the striking emotional challenges, I was a visual learner, which wasnt useful as a blind guy. So I changed my major from pre-medicine to business. My mom read all of my business books to tape, I recorded the lectures, and I listened to the books and lectures multiple times. It turned out I was a better blind student than sighted student. I made straight A's and the Deans List, and upon graduation moved to Atlanta to work for Anderson Consulting (currently Accenture). I was terrified my support system was gone, I didn't know Atlanta, I was working in an industry requiring significant travel. Ultimately, I had to decide which fear I could live with. The fear of failing, or the fear of not knowing my potential.

Griffin: So you became more comfortable with the fear?

Foster: I learned to get comfortable with discomfort. When I was in college, my well-intended parents built a basement for me, just in case I didn't make it in the world. I started thinking of it as the loser basement, and vowed to never spend a day there. If we let others control our expectations for ourselves, whether that be our well-meaning parents or society, where will we end up? We need to live life based on our own vision of greatness.

Griffin: Andersen Consulting is a prestigious Fortune 500 company. What do you think made them seek you out?

Foster: Outstanding companies look for intelligence, drive and a willingness to try. When I explained my journey during the interview, any doubts about my determination were extinguished. In tech its easy to find a developer, but skills have a short shelf life because what will technologies look like in ten years? Whats important is finding people who are smart, naturally curious, and determined. The landscape changes so quickly that hiring for skills is less durable than hiring for traits.

Griffin: Tell me about the software you developed that Oracle said was impossible?

Foster: I taught myself to engineer my own software, and I got so good at it that people would seek me out. One day a colleague called. They had a customer with a blind employee who couldnt do his job because of a problem between their customer relationship management software and screen-reading software.-

So, I said, Yeah, I'll talk to the client, and then I started doing what I always do, which is dig for a solution.

A year or two later, I got an email asking for help with Siebel, and I responded casually saying, I've done this before.

So, we all hopped on a call me, the prospective client and their technical account manager from Oracle, the vendor of the screen-reading software, and my former client and they said, Weve talked to Oracle and the maker of the screen-reading technology and, it's not possible. And then my client said, Actually, Chad's already done it, and I've been using the technology for the last two years. Oracle started sending me clients after that.

Griffin: You were the first blind graduate of the Harvard Business Schools Program for Leadership Development. What did you learn there?

Foster: There are no black and white answers in the world of leadership. Weve got to think about and manage shades of grey. We explored the nuances of real-world business cases and observed them from many different vantage points. I learned a lot from the faculty, as well as my fellow executive classmates.

Griffin: Youre publishing your first book. Can you tell me about that?

Foster: Blind Ambition is a memoir, because the best way for people to digest the lessons Ive learned is to hear the stories from my life. Fundamentally, we all become the stories that we tell ourselves. Its about how I learned resilience by attending the school of hard knocks, being able to distinguish whats inside my sphere of influence, such as my ability to use a computer, write code, and get on stage and deliver an inspirational keynote without notes, and learning how to accept and even embrace things that are outside my sphere.

If you tell yourself youre a victim, that's how youll be. If you tell yourself I've got this, I'm owning this blindness thing, and Ill make it look good, then that's how youll be. And its a self-fulfilling prophecy, because we all become the stories playing in our minds. We can choose to move our mindset from victim to visionary.

We have to be prepared to reinvent ourselves. My blindness came in terrible wrapping paper, but its a gift that enables me to help others in a way thats not otherwise possible.

Griffin: What are some of the major themes that you touch on in your workshops?

Foster: The number one pillar is dealing with change. When going blind, I had to deal with the loss of my self-identity. I never aspired to grow up and be a blind guy, so I had to create a vision of greatness that included my blindness. All of us have faced the question what do you want to be when you grow up? No one said, I want to be a blind guy. But when life changes, we have to figure out how to visualize success. Now, I provide a framework for building resilience. Creating some space to be mindful and intentional about that allows us to respond to challenges more effectively. Coupled with strategy, effort, determination and a plan, its a winning formula.

Griffin: What inspired you to give motivational keynotes in front of thousands of people?

Foster: My tipping point was giving the graduation speech at Harvard. I had a feeling Id be elected so, being a Type-A personality, I met with a professional speaker and prepared my talk before we even voted. When I was elected, I delivered a very moving keynote. One classmate was so moved that he decided to commission an opera inspired by my story. Several others shared how Id inspired them as they faced traumatic situations. I was also moved a feeling of electricity coursed through my body, and I knew I was doing the right thing. At that point I saw how powerfully I could help others if I were to be intentional about it.

Excerpt from:
To Win, Decide Which Fear You Can Live With - Forbes

The Impact of COVID-19 on the Semiconductor Laser Therapeutic Equipment Market Report Research Industry, 2020 report has been added to market.biz offering.

Semiconductor Laser Therapeutic Equipment market2020 reportis a research document that comprises of comprehensive data which boosts and helps the appraisal of every aspect of the Semiconductor Laser Therapeutic Equipment businesses withCovid-19 Impact. It deploys an overview of the baseline and structure of the Semiconductor Laser Therapeutic Equipment market, which summarizes its beneficial or prohibitive aspects liable for regional and global evolution. It outlines the ongoing trends and position of Semiconductor Laser Therapeutic Equipment by thoroughly probing several manufacturers, associations, suppliers, organizations, and industries under the Semiconductor Laser Therapeutic Equipment market.

Apart from this, the globalSemiconductor Laser Therapeutic Equipment Market2020 report provides crucial particulars regarding the categorization, assessed growth trends, distribution network, economical or commercial terms, and many other vital elements related to the Semiconductor Laser Therapeutic Equipment. Rapidly increasing spendable income and innovative products offered by manufacturers are expected to boost Semiconductor Laser Therapeutic Equipment industry over the forecast interval. A vast and growing client base of the Semiconductor Laser Therapeutic Equipment industry creates an opportunity for producers to serve to a significant market and make money.

This report considers the Semiconductor Laser Therapeutic Equipment scope (volume and value) by rivals, regions, product categories, and end-users, previous data, and forecast data. The document also examines the international market competition perspective, leading players in the market, and ongoing trends. It even highlights forthcoming opportunities and challenges, ambiguities and import obstructions, sales lines, and vendors. The research document further estimates the Semiconductor Laser Therapeutic Equipment growth scale as well as forthcoming trends worldwide. Even more, it separates Semiconductor Laser Therapeutic Equipment starting from type to purpose and from comprehensive analysis to key market players and predictions.

Whether you need a birds eye view of the Global Semiconductor Laser Therapeutic Equipmentmarket or a deep dive into a niche segment, heres a report ready and waiting for you. Get Sample PDF @https://market.biz/report/global-semiconductor-laser-therapeutic-equipment-market-qy/534384/#requestforsample.

Sirona Dental Systems GmbHLumenis Inc.Dornier MedTech GmbHPHYSIOMED ELEKTROMEDIZIN AGBiolaseIRIDEX CorporationCynosureCuteraQuanta System S.p.AWON TECHShandong ShensiHelsenGuangdunMedicenWuhan HNCL.H.H. MedicalZhengan MedicalShenzhen Tian

OpthalmologyDermatologyGynecologyDentistryUrologyCardiovascularOthers

Family UsingBeauty UsingMedical Using

Semiconductor Laser Therapeutic Equipment report comprises of the manufacturers data, like price, delivery, advantages, net revenue, enterprise allowance, etc. The entire dataset will offer a better understanding of the competitors across the market. Even more, the study covers assessment from a global viewpoint, which shows a regional growth level, along with the scope, disbursement data, market size, and profit.

The report focuses on competitors dominating the sector and outlining Semiconductor Laser Therapeutic Equipment company profile. The analysis relies on SWOT analysis to reveal the competitive environment of the market throughout the world. Even more, the report includes analysis of current Semiconductor Laser Therapeutic Equipment development, market shares, syndicates and grade of investments with other Semiconductor Laser Therapeutic Equipment chief companies, financial agreements affecting the Semiconductor Laser Therapeutic Equipment market.

Geographically, this document is segmented into different chief territories, containing profits, sales, growth rate and market share (percent) of Semiconductor Laser Therapeutic Equipment in the areas listed below,

South America & including countries

The Middle East and Africa

North America

Europe

Asia-Pacific.

& included countries.

This report will provide you following insights-

Dont see what youre looking for? Enquire here. @https://market.biz/report/global-semiconductor-laser-therapeutic-equipment-market-qy/534384/#inquiry

1.The document offers statistical data about the value (US$) and size (units) for the worldwide Semiconductor Laser Therapeutic Equipment industry between 2019 to 2028.

2.The report also traces the leading market rivals that will create and influence the Semiconductor Laser Therapeutic Equipment business to a greater extent.

3.Extensive understanding of the fundamental trends impacting each sector, although greatest threat, latest technologies, and opportunities that could build the global Semiconductor Laser Therapeutic Equipment market both supply and offer.

4.The report helps the customer to determine the substantial results of major market players or rulers of Semiconductor Laser Therapeutic Equipment sector.

5.The study offers a five-year vital prediction for the Semiconductor Laser Therapeutic Equipment developments, separated by basic product type, end-use group, and various regions across the world.

6.The data analysis present in this report relies on and includes extraction from both elementary and secondary assets.

Buy Latest 2020 Edition of This Report

Ultimately, the conclusion section of the Semiconductor Laser Therapeutic Equipment industry report states the opinion of the industry experts.

Contact Us:

Office Addresses: 420 Lexington Avenue Suite 300

New York City, NY 10170, United States

USA/Canada Tel No: +1-857-2390696

Email:[emailprotected]

You might also like:

Global Sausage Market

Synthetic Human Growth Hormone Market

Global Vision Chart Market

View original post here:
Covid-19 Effect on Global Semiconductor Laser Therapeutic Equipment Market-Industry Demand, Trends, and Forecast 2028 - The Daily Chronicle

LOS ANGELES, United States: QY Research as of late produced a research report titled, Global and Japan Connective Tissue Growth Factor Market Insights, Forecast to 2026. The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The Global and Japan Connective Tissue Growth Factor market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key Companies/Manufacturers operating in the Global and Japan Connective Tissue Growth Factor market include: , BLR Bio LLC, FibroGen Inc, ProMetic Life Sciences Inc, RXi Pharmaceuticals Corp,

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2080969/global-and-japan-connective-tissue-growth-factor-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of Global and Japan Connective Tissue Growth Factor market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global and Japan Connective Tissue Growth Factor Market Segment By Type:

BLR-200IB-DMDOLX-201PBI-4050Others

Global and Japan Connective Tissue Growth Factor Market Segment By Application:

Hypertrophic ScarsOpthalmologyGenetic DisordersLiver FibrosisOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Global and Japan Connective Tissue Growth Factor market.

Key questions answered in the report:

For Discount, Customization in the Report Drop Your Query Here: https://www.qyresearch.com/customize-request/form/2080969/global-and-japan-connective-tissue-growth-factor-market

TOC

1 Study Coverage1.1 Connective Tissue Growth Factor Product Introduction1.2 Market Segments1.3 Key Connective Tissue Growth Factor Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Connective Tissue Growth Factor Market Size Growth Rate by Type1.4.2 BLR-2001.4.3 IB-DMD1.4.4 OLX-2011.4.5 PBI-40501.4.6 Others1.5 Market by Application1.5.1 Global Connective Tissue Growth Factor Market Size Growth Rate by Application1.5.2 Hypertrophic Scars1.5.3 Opthalmology1.5.4 Genetic Disorders1.5.5 Liver Fibrosis1.5.6 Others1.6 Study Objectives1.7 Years Considered 2 Executive Summary2.1 Global Connective Tissue Growth Factor Market Size, Estimates and Forecasts2.1.1 Global Connective Tissue Growth Factor Revenue 2015-20262.1.2 Global Connective Tissue Growth Factor Sales 2015-20262.2 Global Connective Tissue Growth Factor, Market Size by Producing Regions: 2015 VS 2020 VS 20262.3 Connective Tissue Growth Factor Historical Market Size by Region (2015-2020)2.3.1 Global Connective Tissue Growth Factor Retrospective Market Scenario in Sales by Region: 2015-20202.3.2 Global Connective Tissue Growth Factor Retrospective Market Scenario in Revenue by Region: 2015-20202.4 Connective Tissue Growth Factor Market Estimates and Projections by Region (2021-2026)2.4.1 Global Connective Tissue Growth Factor Sales Forecast by Region (2021-2026)2.4.2 Global Connective Tissue Growth Factor Revenue Forecast by Region (2021-2026) 3 Global Connective Tissue Growth Factor Competitor Landscape by Players3.1 Global Top Connective Tissue Growth Factor Sales by Manufacturers3.1.1 Global Connective Tissue Growth Factor Sales by Manufacturers (2015-2020)3.1.2 Global Connective Tissue Growth Factor Sales Market Share by Manufacturers (2015-2020)3.2 Global Connective Tissue Growth Factor Manufacturers by Revenue3.2.1 Global Connective Tissue Growth Factor Revenue by Manufacturers (2015-2020)3.2.2 Global Connective Tissue Growth Factor Revenue Share by Manufacturers (2015-2020)3.2.3 Global Connective Tissue Growth Factor Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Connective Tissue Growth Factor Revenue in 20193.2.5 Global Connective Tissue Growth Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Connective Tissue Growth Factor Price by Manufacturers3.4 Global Connective Tissue Growth Factor Manufacturing Base Distribution, Product Types3.4.1 Connective Tissue Growth Factor Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Connective Tissue Growth Factor Product Type3.4.3 Date of International Manufacturers Enter into Connective Tissue Growth Factor Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Connective Tissue Growth Factor Market Size by Type (2015-2020)4.1.1 Global Connective Tissue Growth Factor Sales by Type (2015-2020)4.1.2 Global Connective Tissue Growth Factor Revenue by Type (2015-2020)4.1.3 Connective Tissue Growth Factor Average Selling Price (ASP) by Type (2015-2026)4.2 Global Connective Tissue Growth Factor Market Size Forecast by Type (2021-2026)4.2.1 Global Connective Tissue Growth Factor Sales Forecast by Type (2021-2026)4.2.2 Global Connective Tissue Growth Factor Revenue Forecast by Type (2021-2026)4.2.3 Connective Tissue Growth Factor Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Connective Tissue Growth Factor Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Market Size by Application (2015-2026)5.1 Global Connective Tissue Growth Factor Market Size by Application (2015-2020)5.1.1 Global Connective Tissue Growth Factor Sales by Application (2015-2020)5.1.2 Global Connective Tissue Growth Factor Revenue by Application (2015-2020)5.1.3 Connective Tissue Growth Factor Price by Application (2015-2020)5.2 Connective Tissue Growth Factor Market Size Forecast by Application (2021-2026)5.2.1 Global Connective Tissue Growth Factor Sales Forecast by Application (2021-2026)5.2.2 Global Connective Tissue Growth Factor Revenue Forecast by Application (2021-2026)5.2.3 Global Connective Tissue Growth Factor Price Forecast by Application (2021-2026) 6 Japan by Players, Type and Application6.1 Japan Connective Tissue Growth Factor Market Size YoY Growth 2015-20266.1.1 Japan Connective Tissue Growth Factor Sales YoY Growth 2015-20266.1.2 Japan Connective Tissue Growth Factor Revenue YoY Growth 2015-20266.1.3 Japan Connective Tissue Growth Factor Market Share in Global Market 2015-20266.2 Japan Connective Tissue Growth Factor Market Size by Players (International and Local Players)6.2.1 Japan Top Connective Tissue Growth Factor Players by Sales (2015-2020)6.2.2 Japan Top Connective Tissue Growth Factor Players by Revenue (2015-2020)6.3 Japan Connective Tissue Growth Factor Historic Market Review by Type (2015-2020)6.3.1 Japan Connective Tissue Growth Factor Sales Market Share by Type (2015-2020)6.3.2 Japan Connective Tissue Growth Factor Revenue Market Share by Type (2015-2020)6.3.3 Japan Connective Tissue Growth Factor Price by Type (2015-2020)6.4 Japan Connective Tissue Growth Factor Market Estimates and Forecasts by Type (2021-2026)6.4.1 Japan Connective Tissue Growth Factor Sales Forecast by Type (2021-2026)6.4.2 Japan Connective Tissue Growth Factor Revenue Forecast by Type (2021-2026)6.4.3 Japan Connective Tissue Growth Factor Price Forecast by Type (2021-2026)6.5 Japan Connective Tissue Growth Factor Historic Market Review by Application (2015-2020)6.5.1 Japan Connective Tissue Growth Factor Sales Market Share by Application (2015-2020)6.5.2 Japan Connective Tissue Growth Factor Revenue Market Share by Application (2015-2020)6.5.3 Japan Connective Tissue Growth Factor Price by Application (2015-2020)6.6 Japan Connective Tissue Growth Factor Market Estimates and Forecasts by Application (2021-2026)6.6.1 Japan Connective Tissue Growth Factor Sales Forecast by Application (2021-2026)6.6.2 Japan Connective Tissue Growth Factor Revenue Forecast by Application (2021-2026)6.6.3 Japan Connective Tissue Growth Factor Price Forecast by Application (2021-2026) 7 North America7.1 North America Connective Tissue Growth Factor Market Size YoY Growth 2015-20267.2 North America Connective Tissue Growth Factor Market Facts & Figures by Country7.2.1 North America Connective Tissue Growth Factor Sales by Country (2015-2020)7.2.2 North America Connective Tissue Growth Factor Revenue by Country (2015-2020)7.2.3 U.S.7.2.4 Canada 8 Europe8.1 Europe Connective Tissue Growth Factor Market Size YoY Growth 2015-20268.2 Europe Connective Tissue Growth Factor Market Facts & Figures by Country8.2.1 Europe Connective Tissue Growth Factor Sales by Country8.2.2 Europe Connective Tissue Growth Factor Revenue by Country8.2.3 Germany8.2.4 France8.2.5 U.K.8.2.6 Italy8.2.7 Russia 9 Asia Pacific9.1 Asia Pacific Connective Tissue Growth Factor Market Size YoY Growth 2015-20269.2 Asia Pacific Connective Tissue Growth Factor Market Facts & Figures by Country9.2.1 Asia Pacific Connective Tissue Growth Factor Sales by Region (2015-2020)9.2.2 Asia Pacific Connective Tissue Growth Factor Revenue by Region9.2.3 China9.2.4 Japan9.2.5 South Korea9.2.6 India9.2.7 Australia9.2.8 Taiwan9.2.9 Indonesia9.2.10 Thailand9.2.11 Malaysia9.2.12 Philippines9.2.13 Vietnam 10 Latin America10.1 Latin America Connective Tissue Growth Factor Market Size YoY Growth 2015-202610.2 Latin America Connective Tissue Growth Factor Market Facts & Figures by Country10.2.1 Latin America Connective Tissue Growth Factor Sales by Country10.2.2 Latin America Connective Tissue Growth Factor Revenue by Country10.2.3 Mexico10.2.4 Brazil10.2.5 Argentina 11 Middle East and Africa11.1 Middle East and Africa Connective Tissue Growth Factor Market Size YoY Growth 2015-202611.2 Middle East and Africa Connective Tissue Growth Factor Market Facts & Figures by Country11.2.1 Middle East and Africa Connective Tissue Growth Factor Sales by Country11.2.2 Middle East and Africa Connective Tissue Growth Factor Revenue by Country11.2.3 Turkey11.2.4 Saudi Arabia11.2.5 U.A.E 12 Company Profiles12.1 BLR Bio LLC12.1.1 BLR Bio LLC Corporation Information12.1.2 BLR Bio LLC Description and Business Overview12.1.3 BLR Bio LLC Sales, Revenue and Gross Margin (2015-2020)12.1.4 BLR Bio LLC Connective Tissue Growth Factor Products Offered12.1.5 BLR Bio LLC Recent Development12.2 FibroGen Inc12.2.1 FibroGen Inc Corporation Information12.2.2 FibroGen Inc Description and Business Overview12.2.3 FibroGen Inc Sales, Revenue and Gross Margin (2015-2020)12.2.4 FibroGen Inc Connective Tissue Growth Factor Products Offered12.2.5 FibroGen Inc Recent Development12.3 ProMetic Life Sciences Inc12.3.1 ProMetic Life Sciences Inc Corporation Information12.3.2 ProMetic Life Sciences Inc Description and Business Overview12.3.3 ProMetic Life Sciences Inc Sales, Revenue and Gross Margin (2015-2020)12.3.4 ProMetic Life Sciences Inc Connective Tissue Growth Factor Products Offered12.3.5 ProMetic Life Sciences Inc Recent Development12.4 RXi Pharmaceuticals Corp12.4.1 RXi Pharmaceuticals Corp Corporation Information12.4.2 RXi Pharmaceuticals Corp Description and Business Overview12.4.3 RXi Pharmaceuticals Corp Sales, Revenue and Gross Margin (2015-2020)12.4.4 RXi Pharmaceuticals Corp Connective Tissue Growth Factor Products Offered12.4.5 RXi Pharmaceuticals Corp Recent Development12.11 BLR Bio LLC12.11.1 BLR Bio LLC Corporation Information12.11.2 BLR Bio LLC Description and Business Overview12.11.3 BLR Bio LLC Sales, Revenue and Gross Margin (2015-2020)12.11.4 BLR Bio LLC Connective Tissue Growth Factor Products Offered12.11.5 BLR Bio LLC Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Connective Tissue Growth Factor Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Connective Tissue Growth Factor Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:
Current and Future Trend of Connective Tissue Growth Factor Market Analysis and Forecast 2020-2026 | BLR Bio LLC, FibroGen Inc - Owned

The research, analysis and estimations about the market have been performed with the steadfast knowledge in this Absorbable and Non Absorbable Sutures Market report. This market report helps to obtain information about all the above factors by giving actionable market insights and comprehensive market analysis. Analysis and discussion of important industry trends, market size, sales volume, and market share are also estimated in this market report. To achieve maximum return on investment (ROI), its very fundamental to figure out market parameters such as brand awareness, market landscape, possible future issues, industry trends & customer behaviour where this Absorbable and Non Absorbable Sutures Market report comes into picture.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-absorbable-non-absorbable-sutures-market&rp

Global Absorbable and Non Absorbable Sutures Market report gives clear idea to Healthcare industry in regard with what is already available in the market, what market anticipates, the competitive environment, and what to be get done to surpass the competitor. This market report serves a great purpose of better decision making and achieving competitive advantage. The report supports in evaluating brand awareness, market landscape, possible future issues, industry trends and customer behaviour with which refined business strategies can be fixed. Absorbable and Non Absorbable Sutures Market report has been comprised of a significant data along with future forecast and detailed analysis on a global and regional level.

Market Analysis and Insights: Global Absorbable and Non-Absorbable Sutures Market

Global absorbable and non-absorbable sutures market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 4% in the above-mentioned forecast period.

The major players operating in theabsorbable and non-absorbable sutures marketreport areThermo Fisher Scientific Inc., Siemens Healthcare GmbH, SeegeneInc, FastSense Diagnostics, Curetis., SolGent Co., Ltd, Mologic, Abbott, altona Diagnostics GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, BioMaxima SA, CTK Biotech, Inc, VivaChek Biotech (Hangzhou) Co., Ltd., Sensing Self, PTE. Ltd, and Hangzhou Biotest Biotech Co., LTD. among other domestic and global players.Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-absorbable-non-absorbable-sutures-market&rp

Sutures are the medical equipments for the usage in cases of surgeries which is in general term known as stitches or surgical threads used insurgeriesfor making connection between the edges of wound which will help to heal it more efficiently. These surgeries can be for either internal or external body system for different tissues healing. There are different sutures available in market according to needs of cases with varying thickness or material as per requirement of surgery. Broadly these sutures are divided into absorbable and non absorbable sutures market. Absorbable suture market is expected to boom in growth rate in forecasted period as it is prove to be better for inner body wound closure whereas in the use of synthetic sources like polymer which are normally manufactured and easily available make market grow. Increase in number of diseases and trauma cases are going to be the driver for the growth of the market whereas rising geriatric population, which is going to be beneficial for market. Moreover Government spending huge amount on healthcare infrastructure development can be opportunity for meeting unmet medical needs in developing regions. However high cost of surgeries and equipment and complicated with other strict regulations on market are restraining factor for the market. There are still some limitations in sutures market which can be a challenge to fulfil market need

This global absorbable and non-absorbable sutures market report provides details of new recent developments, trade regulations, import exportanalysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info onData Bridge Market ResearchGlobal absorbable and non-absorbable sutures market contact us for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Absorbable and Non-Absorbable Sutures Market Scope and Market Size

Global absorbable and non-absorbable sutures market is segmented on the basis of product type, surgery type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Global Absorbable and Non-Absorbable Sutures Market Country Level Analysis

Global absorbable and non-absorbable sutures market is analysed and market size insights and trends are provided by country, product type, surgery type, and end user as referenced above.

The countries covered in the absorbable and non absorbable sutures market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to dominate market share during forecast period due high pace in technological advancement and huge government investment to improve healthcare infrastructure whereas increasing demand for efficient and minimal invasive surgery will expand market growth. Moreover increasing cases of chronic disease and trauma surgeries will also fuel region market growth whereas Asia-Pacific (APAC) is anticipated to expand at the most leading germination pace in the coming years due to developing economies like China, Japan, and India

The country section of the absorbable and non-absorbable sutures market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Absorbable and non-absorbable sutures market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Global absorbable and non-absorbable sutures market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Global absorbable and non-absorbable sutures market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Global Absorbable and Non-Absorbable Sutures Market Share Analysis

Absorbable and non-absorbable sutures market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Global absorbable and non-absorbable sutures market.

Customization Available: Global Absorbable and Non-Absorbable Sutures Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-absorbable-non-absorbable-sutures-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Original post:
Absorbable and Non Absorbable Sutures Market Projected To Grow At A Significant Rate With Industry Analysis || Major Gaints Curetis., SolGent Co.,...

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the American Society of Clinical Oncology (ASCO) has exclusively included Myriads myChoice CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer. The new recommendations, based on clinical trial results, were published in the Journal of Clinical Oncology.

The guideline, titled PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline, where myChoice CDx was the only named commercial companion diagnostic, states that women with ovarian cancer and germline or somatic mutations in BRCA1 or BRCA2 genes and/or genomic instability as determined by Myriad myChoice CDx are recommended by ASCO for PARP inhibitor therapy. The guideline includes myChoice CDx guided management in both newly diagnosed and recurrent ovarian cancer.

We are thrilled to be a part of the rapidly changing landscape in guiding treatment for patients with ovarian cancer. The new ASCO guidelines highlight the large number of recent studies that have gone into improving ovarian cancer patient outcomes, said Thomas Slavin, M.D., FACMG, DABCC, senior vice president of Medical Affairs for Myriad Oncology.

According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. In the United States, it is estimated there will be 21,750 new cases diagnosed and around 13,940 deaths in 2020. A woman's risk of getting ovarian cancer during her lifetime is about one in 78 and the chance of dying from ovarian cancer is about one in 108.

About Myriad myChoice CDx Myriad's myChoice CDx is the most comprehensive homologous recombination deficiency test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice CDx test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). For more information, visit: https://myriad-oncology.com/mychoice-cdx/

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the new ASCO guideline titled PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline and the Companys myChoice CDx testings place in such guideline; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact:Jared Maxwell(801) 505-5027jmaxwell@myriad.com

Investor Contact:Scott Gleason(801) 584-1143sgleason@myriad.com

Here is the original post:
American Society of Clinical Oncology Exclusively Cites myChoice CDx in New Recommendations for Patients with Advanced Ovarian Cancer - BioSpace

Scientists at the Broad Institute have discovered that it isnt enough just to test for mutations to find coronary artery disease, breast cancer or colorectal cancerinstead, its also critical to test for the many small changes across the genome to produce polygenic risk scores (PRS).

The findings are presented in a new study, published Aug. 20 in Nature Communications, and led by the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and by San Francisco-based genetic testing company, Color.

Amit Khera, M.D., associate director of the Broad Institutes Program in Medical and Population Genetics and leader of a research group within the Center for Genomic Medicine at Massachusetts General Hospital and senior author on the study, said he will soon begin offering patients testing based on the findings.

Khera is working with a team of geneticists and genetic counselors in the hospitals Preventive Genomics Clinic to offer a clinical test developed by Color that assesses both monogenic and polygenic risk for heart disease.

This research has real clinical implications for genome interpretation, Khera said. Weve found that the traditional approach of only looking for monogenic risk variants misses an important part of the picture. A persons polygenic risk also plays a crucial role in predicting the development of disease. I suspect that evaluating both will soon become standard in clinical practice.

For the study, researchers focused on breast cancer, coronary artery disease, and colorectal cancer because each disease is associated with what the Centers for Disease Control and Prevention considers a tier 1 genomic condition, meaning there are specific genetic mutations associated with higher risk for developing the condition, according to researchers.

The relationship between the mutations that cause these three genomic conditions and the risk of developing each disease is relatively well understood, authors of the study said. But until now, few researchers have investigated how the interplay between these monogenic variants and someones polygenic risk affects the likelihood of developing disease.

For the study, researchers reviewed genetic information from 80,928 individuals who either participated in case-controlled Color or U.K. Biobank studies, to find the presence of monogenic variants and a patients polygenic risk. The risk score was determined to significantly affect the likelihood of developing a disease associated with a tier 1 genomic condition.

Think about a monogenic variant as a brick, said Julian Homburger, a Color data scientist and co-first author of the paper. A polygenic risk score, then, is like stacking sheets of paper. You can still get to the same sizein this case, the likelihood of developing a diseaseits just a different mechanism. And, what we show is that if you have both of these, they stack on top of each other and contribute to an even greater risk.

Alicia Zhou, CSO at Color and co-author of the paper said the next logical step after testing patients is to monitor them closely, with earlier and more frequent screening. The current approach to screening for genomic conditions is fairly crude, she said. With better information about the risk of genomic diseases, we can refine screening and treatment for people, and hopefully improve patient outcomes.

See the rest here:
New Study from the Broad Finds PRS is Critical Component to Predicting a Range of Diseases - Clinical OMICs News

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the companys Board of Directors. Dr. Love has more than 25 years of global experience in the healthcare and biotechnology/pharmaceutical industry and currently serves as President and Chief Executive Officer of Global Blood Therapeutics.

We are pleased to welcome Ted to our Board of Directors given his distinguished industry expertise and leadership, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. His extensive experience will be a valued addition at this transformational time for our company, with three marketed products, significant development across our pipeline and an expanding global footprint. We look forward to working with Ted on our quest to improve the lives of people with cancer through innovative medicines that address unmet medical needs.

Concurrent with the appointment of Dr. Love, Srinivas Akkaraju, M.D., Ph.D., has resigned from the companys Board of Directors. Dr. Akkaraju has served as a Director since 2003.

I want to thank Srini for his incredible contributions over more than 17 years, added Dr. Siegall. He has played an instrumental role in building Seattle Genetics to the global, multi-product company that it is today.

Prior to Dr. Loves current role at Global Blood Therapeutics, he held executive positions at a number of biopharmaceutical companies including Onyx Pharmaceuticals, Nuvelo, Inc. and Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions at Genentech, where he oversaw the development strategy and execution that led to the approvals of six innovative medicines. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Royalty Pharma and the Biotechnology Innovation Organization, and has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the Companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the extent of development across the companys pipeline, the expansion of its global footprint and its efforts to develop additional cancer medicines to address unmet medical needs. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions as product candidates are evaluated in clinical trials even after promising results in preclinical research. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Go here to read the rest:
Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors - Business Wire

- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour

- 100% Sensitivity and 97.3% Specificity demonstrated in isolated RNA

- Inclusion of PCR-Compatible Universal Lysis Buffer (PULB) in the kit as a workflow option allows labs to circumvent the need for extraction equipment and reagents

GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc., Inc. (Nasdaq: OPGN, OpGen), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that its subsidiary Curetis GmbH has obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus that causes COVID-19.

Developed and manufactured by Curetis team in Germany, the SARS-CoV-2 Kit with PULB uses real-time reverse transcription polymerase chain reaction (RT-PCR) technology for qualitative detection of the SARS-CoV-2 virus isolated from oropharyngeal and nasopharyngeal swab specimens from individuals suspected of COVID-19 by their healthcare provider or for screening of asymptomatic individuals. This kit can be used with RNA isolated by performing standard RNA isolation processes, as well as with oropharyngeal or nasopharyngeal swabs collected in PCR compatible viral transport medium treated with PCR-Compatible Universal Lysis Buffer (PULB) provided in the kit. Including PULB in the kit as a workflow option allows labs to circumvent the need for extraction equipment and extraction kits/reagents, thereby providing operational and workflow efficiencies, time and cost savings. The kit is designed to provide time to results in approximately one hour, and it runs on open real-time PCR instruments such as the QuantStudio 5 Real-Time PCR System and the Bio-Rad CFX96 Real-Time PCR Detection System.

The CE-IVD Marking is an important step in advancing our efforts to support critical COVID-19 testing; the Curetis SARS-CoV-2 Kit with PULB provides additional testing capacity in countries that recognize the CE Mark to test patients, said Johannes Bacher, COO of OpGen.

By launching this new product in Europe, we are committed to helping our distributors and customers to expand the availability of SARS-CoV-2 diagnostic testing, and our own-developed CE-IVD marked SARS-CoV-2 Kit with PULB is expected to help increase availability of these much-needed tests," said Oliver Schacht, PhD, CEO of OpGen. Our customers will benefit from an optimized workflow and a test that delivers great performance and significantly shorter time-to-result at favorable economics compared to many of the commercially available open PCR platform COVID-19 tests including the BGI SARS-CoV-2 kit. Having access to our own SARS-CoV-2 kit allows us to have that product distributed rather than the BGI test kit which we will cease distributing effective immediately.

About OpGen, Inc.OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://www.opgen.com.

Forward-Looking Statements by OpGenThis press release includes statements regarding the commercial launch of a SARS-CoV-2 Kit by OpGens subsidiary, Curetis GmbH. These statements and other statements regarding OpGens SARS-CoV-2 test kits, their commercialization and launch, future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the realization of expected benefits of our business combination transaction with Curetis GmbH, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:Oliver SchachtCEOInvestorRelations@opgen.com

Press Contact:Matthew BretziusFischTank Marketing and PRmatt@fischtankpr.com

Investor Contact:Megan PaulEdison Groupmpaul@edisongroup.com

Source: OpGen, Inc.

Read the original:
OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the...

Carrier screening marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account toUSD 6.47 billion by 2027 growing at a CAGR of 17.40% in the above-mentioned forecast period.

Access Sample Copy Of Carrier Screening Market @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-carrier-screening-market

Carrier Screening market research report gives precise idea about the current situation of the worldwide market, ongoing developments,joint endeavors, size, creation worth, mergers and acquisitions dependent on a few market elements. The report helps with deciding and enhancing each phase in the lifecycle of mechanical procedure that incorporates commitment, securing, maintenance, and adaptation. Additionally, the report offers propelled data and situation about the healthcare business which assists with standing separated in the opposition in this relentless business condition. Moreover, organizations can make out the reaction of the customers to a previously existing item in the market.

The major players covered in the carrier screening market report areF. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Illumina, Inc., QIAGEN, Myriad Genetics, Inc., Pathway Genomics, Siemens Healthcare GmbH, Genomic Health, Inc., Admera Health, deCODE geneticsamong other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa(MEA) and South America separately. DBMR analystsunderstand competitive strengths and provide competitive analysis for each competitor separately.

Key benefits of the report

The global Carrier screening market is also presented to the readers as a holistic snapshot of the competitive landscape within the given forecast period. The report also educates about the market strategies that are being adopted by your competitors and leading organizations. The report also focuses on all the recent industry trends. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of where areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the market.

Global Carrier Screening Market:Segmentation

Carrier screening market is segmented onthe basis of test type, disease type, medical condition, technology and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on test type, carrier screening market is segmented into molecular screening test, and biochemical screening test.

On the basis of disease type, thecarrier screening marketis segmented into cystic fibrosis, tay-sachs, gaucher disease, sickle cell disease, spinal muscular atrophy, and other autosomal recessive genetic disorders.

On the basis of medical condition, the carrier screening market is segmented into pulmonary conditions, hematological conditions, neurological conditions, and others.

On the basis of technology, the carrier screening market is segmented into DNA sequencing, polymerase chain reaction, microarrays, and others.

Carrier screening markethas also been segmented based onthe end use into hospitals, reference laboratories, physician offices & clinics, and others.

Table of Content:

Chapter 1: Carrier Screening market OverviewChapter 2: Carrier Screening market Economic ImpactChapter 3: Competition by ManufacturerChapter 4: Production, Revenue (Value) by Region (2020-2027)Chapter 5: Supply (Production), Consumption, Export, Import by Regions (2020-2027)

Chapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: market Analysis by ApplicationChapter 8: Carrier Screening Market by Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Carrier Screening Market Geographic AnalysesChapter 11.1: North AmericaChapter 11.2: EuropeChapter 11.3: Asia-PacificChapter 11.4: South AmericaChapter 12: Carrier Screening Market Effect Factors AnalysisChapter 13: Carrier Screening Market Forecast (2020-2027)Chapter 14: Related ReportsChapter 15: Appendix

Get Detailed Table Of[emailprotected]https://www.databridgemarketresearch.com/toc/?dbmr=global-carrier-screening-market

About Us:Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

See the article here:
Global Carrier Screening Market COVID-19 Impact Analysis 2020| Competitive Scenario And Dynamics By Myriad Genetics, Inc., Pathway Genomics, Siemens...

SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced the appointment ofPaul J. Diazas President and Chief Executive Officer, effective August 13, 2020. He will also serve on the Companys Board of Directors. Mr. Diaz brings toMyriad Geneticsmore than three decades of executive leadership and business transformation experience in healthcare across a variety of healthcare segments.

Paul is an exceptional leader and executive with extraordinary passion, vision, experience, and operational skills, saidS. Louise Phanstiel, Chair of Myriads Board of Directors. His focus on building high performing teams, and instilling a culture that empowers people to deliver high quality patient care, distinctive customer service and innovation, will be important to supporting Myriads mission and growth. We are excited to have Paul assume the leadership of Myriad Genetics and chart the course to realize the Companys full potential. We look forward to officially introducing Paul during our fourth quarter earnings call. Myriad is dedicated to providing vital information to physicians, patients and their families that enables them to make better decisions about their health and treatment planning. Pauls personal dedication, throughout his career, to patients and their care will be critical in advancing Myriads vision of being a trusted advisor transforming patients lives worldwide with pioneering molecular diagnostics.

I am very excited to join the talented management team and Board of Directors of Myriad Genetics, an organization dedicated to helping patients and physicians identify the risk of developing disease and accurately diagnosing disease and disease progression, commented Paul. Our goal is to empower patients, as consumers, and their physicians and our payer partners with the information and data to help guide their treatment decisions, to improve clinical outcomes and lower healthcare costs.I am equally excited about Myriads potential for innovation and growth.The Company has a tremendous opportunity to transform its business, and strategically position itself for sustainable, profitable growth. We will look to leverage the companys culture of innovation and revitalize our approach to the commercializing of its products and customer service levels.

Mr. Diaz served as the President and Chief Executive Officer and Executive Director and Director of Kindred Healthcare, Inc. for over ten years, where he led the growth, revitalization and diversification of the business that positioned Kindred as the largest provider of post-acute health care services in the United States. Most recently, Mr. Diaz was a Partner at Cressey & Company LP, a private equity firm focusing on healthcare services and HCIT companies. Mr. Diaz is an experienced director and operating executive, having served as an executive and board member of multiple public and private companies. He currently serves on the board of DaVita, Inc. (NYSE: DVA) and is a member of the Board of Trustees of Johns Hopkins Medicine. Mr. Diaz graduated from The American University with a B.S. in Business Administration and with a J.D. from The Georgetown University Law Center.

Heidrick & Struggles led the search process for Myriad.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to realizing the Companys full potential; officially introducing Paul during the Companys fourth quarter earnings call; advancing Myriads vision of being a trusted advisor transforming patients lives worldwide with pioneering molecular diagnostics; the Companys potential for innovation and growth; the Companys tremendous opportunity to transform its business, and strategically position itself for sustainable, profitable growth; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

See original here:
Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors - GlobeNewswire

MONCTON, New Brunswick--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, is pleased to announce it has partnered with Medical Cannabis by Shoppers(Shoppers) on Phase 2 of Shoppers Pilot Program powered by software partner TruTrace Technologies Inc. (CSE: TTT; OTCQB: TTTSF) (TruTrace).

The program is designed to genetically finger-print all participating cannabis products, tracking them throughout the supply chain, from genome to patient, in order to provide real-time information about the composition of each cannabis product used by Medical Cannabis by Shoppers customers.Organigram will provide cannabis products to Shoppers for use in the tracking program.

Standardized and validated testing of medical cannabis, ensuring consistent quality and efficacy, are critical to the products value as a viable treatment option. Likewise, product information such as strain composition and potency can help healthcare practitioners and patients make more informed and confident decisions about their medical cannabis treatment regimens.

Organigram is proud of our long-standing commitment to our medical cannabis community. From the development of innovative products to the support offered by our patient care team and programs, patients and their needs are at the heart of our medical cannabis business, says Greg Engel, CEO, Organigram. We also recognize how critical consistency is to patients and their healthcare providers so are pleased to partner with Shoppers, providing our products so that they can be followed from raw material to finished product, to offer them important, useable product insights.

Using Trutraces StrainSecure system, the program collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the technology.

As jurisdictions around the world have begun to legalize and adopt cannabis as a medical treatment, there has been an influx ofnew breeders and growers and a profusion of new cannabis strains, each with a different representation of at least 500 known metabolites. Subtle changes in the chemical expression of various strains, whether by genetic structure or environmental conditions, may have significant clinical effects on the patients using this treatment option.With so many strains available, and with relatively limitedinformationon strain composition or genetic lineage and their relation to their chemical output, patients havelittleability to control what they aretaking over time.

In the absence of assigned drug identification numbers (DIN)for cannabis products, quantifying the genetics and metabolomics, as well as potency and equivalencies ofcannabis products is of interest to producers, distributors, shippers, government agencies, payers, clinicians and patients.

Maintaining an effective traceability ecosystem about these details throughout the supply chain is a component of providing consistent medicine, says Engel.

Using TruTrace technology, Shoppers has partnered with University Health Network in Toronto (UHN) to launch Medical Cannabis Real World Evidence (MCRWE), a new ground-breaking study on cannabis and health which will track outcomes with TruTrace validated product for the first time in history.

This novel observational study is targeting a minimum of 2,000 patients who will be followed over a 24-week period. Enrolled patients will have access to certain fully verified products on the Medical Cannabis by Shoppers platform, which have been tested for detailed cannabinoid and terpene profiles.More information about the study can be found here.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, AnkrOrganics and Trailblazer. Organigram's facilityis located inMoncton, New Brunswick and the Company is regulated by theCannabis Act and theCannabis Regulations(Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as plans, expects, estimates, intends, anticipates, believes or variations of such words and phrases or state that certain actions, events, or results may, could, would, might or will be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors that change supply quantities; risks associated with international jurisdictions including regulatory risk; receipt of any required permits from Health Canada and other authorities; including general risks related to COVID-19 and risks as disclosed in the Companys most recent annual information form, managements discussion and analysis and other Company documents filed from time to time on SEDAR (see http://www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see http://www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

See the original post here:
Organigram Joins Medical Cannabis by Shoppers Inc. and TruTrace in Effort to Track Source and Genetics of Cannabis Used by Medical Patients - Business...

Photo Courtesy Jeff Fitlow

By Rishab Ramapriyan 8/18/20 9:18pm

On Tuesday, Will Rice College announced that the remainder of Orientation Week activities will be conducted fully online. The announcement came after a second Will Rice O-Week advisor tested positive for COVID-19 this morning.

According to the Dean of Undergraduates Bridget Gorman, this decision was not mandated by the Rice University administration, but rather reached locally by the Will Rice magisters and O-Week coordinator team. In their email to the Will Rice advising team and new student cohort, the coordinators said that this decision was made out of an abundance of caution.

We take this action to minimize the risk to your own health and to limit further spread of the virus, the coordinators wrote.

Advisors and new students living on-campus are restricted to their floors as mandated campus-wide, but they are still able to use outdoor spaces, according to Rahul Popat, the Will Rice College President. As long as students follow the guidelines set by the Culture of Care Agreement, they are free to exit their rooms.

Vice President of Administration Kevin Kirby, who chairs the Crisis Management Advisory Committee, said that Rices team of 17 contact tracers promptly responded to both Will Rice cases. Any individuals who met the Centers for Disease Control and Prevention criteria for close contact (within 6 feet for more than 15 minutes) were quarantined and tested using a molecular test (polymerase chain reaction test). A few additional advisors who believed that they had been in contact with the COVID-19-positive students voluntarily quarantined themselves, according to Kirby. All of the quarantined students have tested negative and there have been no additional cases in the Will Rice community as of this morning.

New students and advisors had all received an antigen rapid test from CVS on move-in day, but antigen tests have a lower sensitivity and specificity than molecular tests. As such, all O-Week participants will undergo a follow-up molecular test by the end of this week. However, the entire Will Rice advising team and new student cohort will be tested via the molecular test either today or tomorrow as a precaution, according to Kirby. Results from Rices molecular tests, which are provided by Houston Methodist and Baylor Genetics, are returned within 48 hours, but Kirby said that the tests are often being returned in 24 hours.

Enjoy what you're reading?Signup for our newsletter

We'll go through the whole college and test everybody, Kirby said. We'll see if there are any [COVID-19 positive students] that have been missed or any new infections and sort of sweep through and get everybody today or tomorrow. And these tests are very accurate.

According to Kirby, there was an additional Will Rice advisor who tested positive for COVID-19, however this student had fully recovered from a previous COVID-19 infection and Student Health Services determined that they did not pose any risk for transmission, according to Kirby. The CDC notes this possibility in their guidance on discontinuing isolation measures.

Recovered persons can continue to shed detectable SARS-CoV-2 RNA in upper respiratory specimens for up to 3 months after illness onset, albeit at concentrations considerably lower than during illness, in ranges where replication-competent virus has not been reliably recovered and infectiousness is unlikely, the CDC writes. Studies have not found evidence that clinically recovered persons with persistence of viral RNA have transmitted SARS-CoV-2 to others.

Following this guidance, Kirby said that this additional Will Rice advisor was not isolated, but continues to be monitored.

Kirby said that 833 new students were given rapid tests on Saturday and Sunday, and three students tested positive. Those who tested positive could either move in to Sid Richardson College, the designated isolation housing, or return home. No more than two students have occupied Sid Rich at any point thus far, Kirby noted.

Campuswide, there have been 4,595 tests administered between August 1 and August 17, and 11 people (3 staff, 7 undergraduates, 1 graduate student) have tested positive, based on a recent update from Crisis Management. Kirby said that Rice will be administering 4,500 tests per week by the first week of classes.

Gorman said that two restrictions have been added to the campuswide O-Week program as precautionary measures. First, all remaining cross-college events have been canceled for the week. Second, students will not be allowed to eat meals together in the college commons, and must eat meals in their dorm rooms or outdoors in a physically-distanced manner.

We're testing everybody this week, as we're doing every week, Gorman said. So we're going to know in the next couple of days whether we're seeing any more spread or whether it's just these two cases at Will Rice.

Gorman said that she hopes to remove the restriction on college commons dining after O-Week, but will decide after more test results are returned.

I think by the weekend after we've gone through and gotten the test results back on everybody on campus and we get a sense about where we're at, we will make a decision at that point, Gorman said. But in preparation, just in case, we are going to ramp up our outside furniture.

Kirby said that while the COVID-19 positivity rate is substantially lower on campus than in Houston, it is important to continue all safety precautions and adapt to changing conditions.

We have to be very careful and wary right about that and we need to not have a false sense of optimism here, Kirby said. That's why it's important that we continue to do all the safety precautions ... and we continue to do our testing rigorously and often. We're prepared to make changes like we already have. I'm sure we'll continue to make changes over the course of the fall semester.

[8/18/2020 at 11:15 p.m.] The story was updated with correct information about the movement of on-campus students. Will Rice President Rahul Popat clarified that on-campus students are not restricted to their rooms.

[8/18/2020 at 11:45 p.m.] The story was updated with information about an additional Will Rice advisor who tested positive for COVID-19, but was determined to not pose any risk for transmission.

[8/19/2020 at 3:10 p.m.] The story was updated with statistics from on-campus COVID-19 testing.

See original here:
Will Rice College O-Week moves online after two advisors test positive for COVID-19 - The Rice Thresher

A-level student Kilian Robinson.

Kilian Robinson, 18, of Egton, consistently achieved the highest possible grades for his subjects Biology, Chemistry and Maths over the past two years.

But he was horrified on Thursday to discover that his centre assessment grades had been reduced from A*A*A* to ABB by the controversial Government algorithm, despite him not once attaining anything lower than an A.

He said today (Tues) that Imperial College London had indicated they would keep his place on a Biological Scienes course open to him if he successfully appealed.

Yesterday's Governments U-turn means Kilian has attained his grades and fulfilled his side of the bargain.

He is now waiting to hear back from Imperial College London, having emailed them after the dramatic climbdown was announced.

They said they would honour my offer if I got the grades now Ive got them," he said.

The fight isnt over. Everyone is anxious about it and what if the course is full?

Its a massive problem, yes Ive got my grades but its still to be resolved.

Kilian was offered a place on a Molecular Genetics course in Edinburgh, despite not his results being initially downgraded, but he declined as he has set his heart on a place at Imperial College London.

Read more:
Whitby student welcomes A-level U-turn - but still left in limbo over his future - Whitby Gazette

This story was originally published on Newsroom.co.nz and is republished with permission

With investigations into a coolstore and freight as a potential pathway for the latest outbreak of Covid-19, what does science say about surfaces and refrigeration?

Surfaces at a Mount Wellington coolstore are being tested for Covid-19 in an effort to uncover the route of the virus back into the community.

Ryan Anderson/Stuff

Americold in Mount Wellington, Auckland, where a south Auckland man with coronavirus works.

A worker at the coolstore has tested positive for the disease. How he caught it is still a mystery. The possibility it could have come in on overseas freight arriving at the coolstore is being investigated.

Were not ruling that out, said Director-General of Health Ashley Bloomfield, We want to get to the bottom of that.

READ MORE:* Coronavirus: Extension to Covid-19 lockdown likely, says disease modelling expert* Coronavirus: Rapid 'cluster busting' to find Covid-19 outbreak source could nip other clusters in the bud* Coronavirus: Auckland cool storage facility tested over concern Covid-19 entered NZ via freight* Coronavirus: Aucklanders should be wearing masks, experts say

The coolstore environment has been swabbed and test results are expected back today.

Yesterday, three other workers from the coolstore returned positive tests for Covid-19.

It's possible the workers were either infected by contaminated goods, or the virus was brought into the workplace after it was caught elsewhere, possibly by the man who was first diagnosed.

Two branches of the coolstore have been closed. One in Mount Wellington, where the man worked, and another close to Auckland Airport.

Genomic sequencing is still underway, but as of yesterday afternoon there hasnt been a link between genome patterns of cases in border quarantine and the genome pattern of the coolstore-related cases.

University of Auckland professor Shaun Hendy said the fact the source of the outbreak hadnt been identified yet was concerning.

MYTCHALL BRANSGROVE/STUFF

Tests are still ongoing to trace the pandemics source.

To date, the genomic information suggests this cluster is not linked to a managed isolation and quarantine facility. The business itself is linked to international freight, air and sea, which does suggest that this is a possible entry route, whether via packaging, or more likely, via person-to-person.

Like many things Covid-19 related, the science of transmission isnt clear-cut; what studies have been done are often laboratory-based.

Surface transmission is considered a lower risk for virus transmission than person-to-person contact but cold environments, such as meat works, have been at the centre of overseas clusters.

Cant touch this

New Zealands news came as China has again claimed it has found the virus on the outer packaging of frozen prawns imported from Ecuador.

Chinas state television said it was found during a routine inspection of a restaurant in Wuhu city.

Its not the first report of this in China. Since July, several other Chinese cities have also reported cases, including the port cities of Xiamen and Dalian leading to imports from three suppliers being suspended.

After nucleic acid sequence analysis and expert judgment, the test results suggested that the container environment and the outer packaging of the goods of the three companies were at risk of contamination by the new coronavirus, and the companies food safety management system was not in order, the General Administration of Customs said in a statement.

The director of the organisation, Bi Kexi, told reporters: "Experts believe that the results do not mean they are contagious but that the companies' food safety management systems are not well implemented," Bi Kexin, director General Administration of Customs said.

For international packaging to be the cause of this outbreak, a chain of events would need to have taken place. Enough of the virus landing - on packaging - perhaps through a person coughing droplets onto a surface - would be the first step. The droplets would need to remain viable throughout the journey to the New Zealand coolstore.

Then the virus on the packaging would need to find a pathway to a person, possibly through someone touching the package and then touching their face.

Studies have been done on how long the virus survives on different surfaces. Traces of the virus were detected on plastic and steel up to three days after contamination and on cardboard for up to one day.

In chilled conditions, the virus can survive longer. One study looking at the survival time of the virus in a test tube found at 4C, the virus survived for 14 days. At 37C it lasted just one day.

The other factor is the amount of virus on a surface. A recent letter published in The Lancet suggests the risk of surface transmission has been exaggerated.

None of these studies present scenarios akin to real life situations, the letter said.

The Rutgers University professor of microbiology, biochemistry and molecular genetics Emanuel Goldmans issue was that in real life the amount of virus would likely be several orders of magnitude smaller.

While saying he believed in erring on the side of caution, he thought the risk was low.

In my opinion, the chance of transmission through inanimate surfaces is very small, and only in instances where an infected person coughs or sneezes on the surface, and someone else touches that surface soon after the cough or sneeze (within one - two hours).

While the risk is considered low, its still a possibility.

In a Chinese mall, several people caught the virus in January despite not being in direct contact with the one person at the mall who was known to have it. A restroom and elevator buttons were considered to be places where these people may have touched contaminated surfaces.

Covid and chill

Cold work environments have been at the centre of outbreaks. The exact reasons why arent clear, although theres plenty of speculation.

In the US 17,358 cases of coronavirus were recorded from meat and poultry factory workers.

An abattoir in Germany was closed after 1500 workers were infected and in Melbourne at least three abattoirs were closed after outbreaks occurred. Abattoir-related outbreaks have also occurred in the United Kingdom, France, Brazil, Denmark and the Netherlands.

There are a few factors likely to be at play and theyre not related to dead animals.

Physical distancing on a production line can be hard as often people work shoulder-to-shoulder. Shifts are long, and casualised employment can make people less likely to stay home when ill because they cant afford time off.

Background noise can mean shouting is needed to communicate, increasing the risk of droplet spread. Air filtration systems push air around, potentially spreading droplets further.

No sunlight and cold conditions extend the life of the virus.

The conditions at the New Zealand coolstore where cases have emerged may not be identical to overseas abattoirs, but there's a chance cold may play a role in giving any virus in the environment a chance to live longer.

This story was originally published on Newsroom.co.nz and is republished with permission

Read the original:
Coronavirus: Cold temperatures are where Covid-19 thrives - Stuff.co.nz

DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration Market by Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, TENS, TMS), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global nerve repair and regeneration market is projected to reach USD 9,781.2 million by 2025 from USD 6,339.7 million in 2020, at a CAGR of 9.1%

The growth in this market is driven by a high incidence of nerve injuries, a growing prevalence of neurological disorders, an increasing geriatric population, and rising government support for neurologic disorder research.

The biomaterial as a segment is anticipated to grow at the fastest growth rate during the forecast period.

Based on product type, the nerve repair and regenerations market is segmented into neurostimulation and neuromodulation devices and biomaterials. The biomaterials segment is expected to grow at the highest growth rate during the forecast period. This can primarily be attributed to the high incidence of nerve injuries. Rising government support for neurologic disorders is also one of the major factors to drive the growth of the biomaterials market globally.

The internal neurostimulation and neuromodulation segment is accounted for the largest share during the analysis period.

Based on the neurostimulation and neuromodulation application, the nerve repair and regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation and neuromodulation segment is accounted for the largest share during the forecast period. This can primarily be attributed to the increasing incidence of neurological disorders across the globe.

Asia Pacific is estimated to register the highest CAGR during the study period.

In this report, the nerve repair and regeneration market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in the Asia Pacific is projected to grow at the highest growth rate during the forecast period. Economic growth in the countries of this region, large population base, rising prevalence of neurologic diseases, rising standard of living, growing demand for quality medical care, and increasing healthcare spending will drive the market in the region over the forecast period.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 Nerve Repair & Regeneration Market Overview

4.2 Nerve Repair & Regeneration Market: Geographic Growth Opportunities

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Incidence of Nerve Injuries

5.2.1.2 Rising Geriatric Population and Subsequent Growth in the Prevalence of Neurological Disorders

5.2.1.3 Rising Government Support for Neurologic Disorder Research

5.2.2 Opportunities

5.2.2.1 Emerging Markets

5.2.2.2 Potential of Stem Cell Therapy in Nerve Repair and Regeneration

5.2.2.3 Rising Research in the Field of Neurology

5.2.3 Challenges

5.2.3.1 Donor-Site Morbidity

5.2.3.2 Difficulties in Treating Large Nerve Gaps

5.2.3.3 Stringent Regulatory Frameworks and Time-Consuming Approval Processes

5.2.3.4 Greater Preference for Drug Therapies Over Nerve Repair and Regeneration Products

5.2.3.5 Dearth of Trained Professionals

5.2.3.6 Product Recalls

5.3 Impact of COVID-19 on the Nerve Repair and Regeneration Market

6 Nerve Repair and Regeneration Market, by Product

6.1 Introduction

6.2 Neurostimulation and Neuromodulation Devices

6.3 Biomaterials

7 Nerve Repair and Regeneration Market, by Application

7.1 Introduction

7.2 Neurostimulation & Neuromodulation Applications

7.3 Nerve Repair & Regeneration Biomaterials Market, by Application

8 Nerve Repair and Regeneration Market, by Region

8.1 Introduction

8.2 North America

8.3 Europe

8.4 Asia-Pacific

8.5 Rest of the World (Row)

9 Competitive Landscape

9.1 Overview

9.2 Market Share Analysis, 2019

9.3 Competitive Scenario

9.3.1 Product Launches and Approvals

9.3.2 Partnerships, Collaborations, Mergers, and Agreements

9.3.3 Expansions

9.3.4 Acquisitions

9.3.5 Other Developments

9.4 Competitive Leadership Mapping (2019)

9.4.1 Visionary Leaders

9.4.2 Innovators

9.4.3 Dynamic Differentiators

9.4.4 Emerging Companies

10 Company Profiles

10.1 Medtronic, plc

10.2 Boston Scientific Corporation

10.3 Abbott Laboratories

10.4 Axogen, Inc.

10.5 Baxter International, Inc.

10.6 Livanova, plc

10.7 Integra Lifesciences

10.8 Polyganics

10.9 Neuropace, Inc.

10.10 Soterix Medical, Inc.

10.11 Nevro Corp.

10.12 Synapse Biomedical, Inc.

10.13 Aleva Neurotherapeutics

10.14 Collagen Matrix, Inc.

10.15 Kerimedical

10.16 Biowave Corporation

10.17 Neurosigma

10.18 Neuronetics, Inc.

10.19 TVNS Technologies GmbH

10.20 Gimer Medical

For more information about this report visit https://www.researchandmarkets.com/r/n8ux49

View original post here:
Global Nerve Repair and Regeneration Market 2020-2025: The Potential of Stem Cell Therapy in Nerve Repair and Regeneration Fuels Opportunity -...